Terumo BCT04.20.20
Data from a new study suggests that a medical device that uses vitamin B2 and ultraviolet light for treating human blood products is effective against the virus that causes COVID-19. The study results, generated by Terumo BCT in collaboration with top researchers from Colorado State University, have been accepted for publication by Vox Sanguinis, a peer-reviewed medical journal covering hematology.
Blood is considered vital medicine, and it is the backbone of the healthcare system. While there is no evidence that blood transfusions transmit COVID-19, some blood centers are using Mirasol to treat platelets and plasma as an additional layer of safety.
In some parts of the world, healthcare providers also treat convalescent plasma with Mirasol.1 The International Society for Blood Transfusion (ISBT) Global Blood Safety Working Party recommends, where feasible, pathogen inactivation of plasma to control residual risks of transfusion transmitted infection diseases and to ally concern about possible superinfections with SARS-CoV-2, the virus that causes COVID-19.2
Using riboflavin (vitamin B2) and ultraviolet light, Mirasol is designed to reduce the pathogen load of various disease-causing agents such as viruses, parasites and bacteria in blood products before they are transfused to patients. Mirasol also inactivates white blood cells to help reduce certain transfusion reactions.
Curious how medtech's top companies are responding to the COVID-19 pandemic? Get insights into each company's actions by clicking here.
“Mirasol is one of the tools we are using to help equip healthcare providers in their fight against COVID-19,” said Antoinette Gawin, President and Chief Executive Officer, Terumo BCT. “We are deploying our existing innovations to benefit as many patients as possible.”
Mirasol is CE marked for platelets, plasma and whole blood and is in routine use in more than 20 countries throughout Europe, the Middle East, Africa, Asia and Latin America. The system is not approved for sale in the U.S. and Canada.
There are no approved devices or therapies for specific treatment of COVID-19.
References
1 Epstien, Jay, Burnouf, Theirry, On behalf of the ISBT Working Party on Global Blood Safety. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma. https://isbtweb.org/fileadmin/user_upload/Points_to_consider_in_the_preparation_of_COVID_convalescent_plasma_-_200331_ISBT_WP_GBS_Final.pdf
2 Study funded by Terumo BCT and conducted at Colorado State University, Fort Collins, Colo. Authors: From Terumo BCT: Shawn D. Keil, Susan Yonemura and Nicole K. Dart. From CSU's Department of Biomedical Sciences, Fort Collins, Colo., Izabela Ragan and Richard Bowen. From CSU's Infectious Disease Research Center, Fort Collins, Colo. Lindsay Hartson.
Blood is considered vital medicine, and it is the backbone of the healthcare system. While there is no evidence that blood transfusions transmit COVID-19, some blood centers are using Mirasol to treat platelets and plasma as an additional layer of safety.
In some parts of the world, healthcare providers also treat convalescent plasma with Mirasol.1 The International Society for Blood Transfusion (ISBT) Global Blood Safety Working Party recommends, where feasible, pathogen inactivation of plasma to control residual risks of transfusion transmitted infection diseases and to ally concern about possible superinfections with SARS-CoV-2, the virus that causes COVID-19.2
Using riboflavin (vitamin B2) and ultraviolet light, Mirasol is designed to reduce the pathogen load of various disease-causing agents such as viruses, parasites and bacteria in blood products before they are transfused to patients. Mirasol also inactivates white blood cells to help reduce certain transfusion reactions.
Curious how medtech's top companies are responding to the COVID-19 pandemic? Get insights into each company's actions by clicking here.
“Mirasol is one of the tools we are using to help equip healthcare providers in their fight against COVID-19,” said Antoinette Gawin, President and Chief Executive Officer, Terumo BCT. “We are deploying our existing innovations to benefit as many patients as possible.”
Mirasol is CE marked for platelets, plasma and whole blood and is in routine use in more than 20 countries throughout Europe, the Middle East, Africa, Asia and Latin America. The system is not approved for sale in the U.S. and Canada.
There are no approved devices or therapies for specific treatment of COVID-19.
References
1 Epstien, Jay, Burnouf, Theirry, On behalf of the ISBT Working Party on Global Blood Safety. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma. https://isbtweb.org/fileadmin/user_upload/Points_to_consider_in_the_preparation_of_COVID_convalescent_plasma_-_200331_ISBT_WP_GBS_Final.pdf
2 Study funded by Terumo BCT and conducted at Colorado State University, Fort Collins, Colo. Authors: From Terumo BCT: Shawn D. Keil, Susan Yonemura and Nicole K. Dart. From CSU's Department of Biomedical Sciences, Fort Collins, Colo., Izabela Ragan and Richard Bowen. From CSU's Infectious Disease Research Center, Fort Collins, Colo. Lindsay Hartson.
